| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.03 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.04 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.07 | 0.04 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.04 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.04 |
| mRNA | tubastatin A | GDSC1000 | pan-cancer | AAC | -0.062 | 0.04 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.061 | 0.04 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.095 | 0.04 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.07 | 0.04 |